Nasal Cavity and Paranasal Sinus Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
Conditions: Nasal Cavity Cancer; Paranasal Sinus Cancer; Camrelizumab; Induction Chemotherapy; Intensity Modulated Radiotherapy; Concurrent Chemotherapy Intervention: Drug: camrelizumab Sponsor: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2021 Category: Research Source Type: clinical trials
